Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...

New study published in Genetics in Medicine reveals transformative impact of Ambry's Patient for Life reanalysis program.

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting revenue and backlog. The AI precision medicine company grew core revenues 32% ...

Tempus AI TEM is currently in its 10 th year of business and on track to hit a long-anticipated milestone. In its first-quarter 2025 earnings report, the AI-driven healthcare company guided full-year ...